ABBV

AbbVie Inc. (ABBV) | Rumor.io

AbbVie

ABBV

Attention (50-day avg)0.01%

Attention rank (50-day avg)#346

Bullish sentiment (50-day avg)92%

Price to earnings ratio75

Market capitalization470.5B

Earnings per share3.55

Dividend yield (TTM)2.6%

Revenue (annual)61.2B

Net income (annual)4.2B

Social

What share of all stock conversation is about ABBV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.03% -0.03	0.03% +0.02	0.02% +0	0.02% -0.02

Sep 28

AbbVie's JUVMO (tavapadon) has been FDA-approved for Parkinson's disease, making it the first selective D1/D5 agonist for adults with the condition.
257 of 273 patients in a clinical trial went 85 weeks without starting levodopa, a common treatment for Parkinson's disease, indicating the potential effectiveness of JUVMO.
AbbVie's Cerevel buyout has delivered, with the FDA giving the go-ahead to JUVMO as a new treatment and the first selective D1/D5 receptor in adults with Parkinson's disease.

Generated by AI

Sentiment

Of the messages about ABBV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	97.03% -2.97	97.32% +14.23	87.39% -2.68
Bearish	0% 0	2.97% new	2.68% -14.23	12.61% +2.68

Bullish· Aug 27

AbbVie's phase 2 study for spinal cord injuries showed excellent results, with a 100% success rate, and the company is fully funded to Q1 2028.
The market has only 10% penetration for spinal cord injury, with AbbVie's current market cap representing a potential 78% return if the company achieves full market penetration.
AbbVie's stock is expected to experience substantial moves higher, potentially leading to a buyout, with one potential timeframe being October or November.

Bearish· Mar 18

$ABBV's AML treatment failed in several Phase 3 trials, including VIALE-M and VIALE-T, raising concerns about its effectiveness.
AbbVie's stock price declined due to the potential threat of Protagonist Therapeutics' FDA-approved ICOTYDE, a plaque psoriasis treatment that could rival AbbVie's Skyrizi drug.
The stock's sharp breakdown below $220 to $207.93 on higher volume indicates a possible technical breakdown and potential for further downside continuation.

Generated by AI

Topics

Of the messages about ABBV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	6.67%	14.02%	29.32%	37.25%
Announcements	40%	59.03%	33.9%	7.15%
Technical Analysis	53.33%	10.51%	5.74%	1.8%
Earnings	0%	4.85%	3.04%	22.05%
Macro	0%	11.59%	27.83%	31.65%
Controversies	0%	0%	0.17%	0.11%

Earnings· Jul 31

AbbVie (ABBV) reported Q2 2026 earnings with adjusted EPS of $3.65, beating estimates of $3.61, and revenue of $16.99B, also exceeding estimates of $16.77B.
The company's adjusted diluted EPS guidance range was updated from $13.91-$14.11 to $13.87-$14.07, reflecting the anticipated dilutive impact from the proposed acquisition of Apogee Therapeutics.
AbbVie's Q2 2026 earnings were driven by strong performance in its immunology portfolio, with revenue of $8.79B, a 15.1% YoY increase, and adjusted EPS of $3.65, a 22.9% YoY increase.

Analysts· Jun 23

Canaccord Genuity issued a price target of $273.00 for ABBV on June 23, 2026.
The price target was set due to a positive outlook for the company.
The price target of $273.00 is an adjusted amount.

Announcements· Jul 31

AbbVie reported Q2 2026 earnings with revenue of $16.99B, a 10.2% YoY increase, and adjusted EPS of $3.65, a 22.9% YoY increase.
The company raised its full-year revenue guidance by $300M, with Skyrizi and Rinvoq continuing to offset Humira's decline, and all three franchises compounding above 20%.
AbbVie acquired Apogee Therapeutics for $10.9B, adding an IL-13 asset for atopic dermatitis and asthma, and will use this asset in its IL-13/TSLP program.

Controversies· Apr 7

Multiple law firms have announced shareholder class action lawsuits against AbbVie Inc. (NYSE: ABBV) for alleged securities fraud and losses.
The lawsuits aim to recover losses for investors who have suffered damages due to AbbVie's alleged misconduct.
The cases involve several law firms, including Schall Law Firm, Bernstein Liebhard LLP, and Kessler Topaz Meltzer & Check, LLP, which have filed separate lawsuits against AbbVie.

Macro· Mar 18

ABBV is up 3.35% in the last 25 years, according to a comparison with the DGRO ETF.
ABBV's performance is a key consideration for investors weighing the merits of the DGRO ETF.
The comparison highlights the long-term growth potential of ABBV versus the broader market represented by the DGRO ETF.

Technical Analysis· Mar 18

$ABBV has broken below key support areas, triggering stop losses, with a current price of $208.71 and a 5.03% decline.
The daily RSI for $ABBV has hit 30, a level previously reached during major events, such as the Trump tariffs and a failed drug launch.
$ABBV is sitting at critical support, with a sharp breakdown from the mid-$220s to around $211, and some analysts expecting more downside continuation.

Generated by AI

Community

Of the messages about ABBV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	18.23%	70.53%	62.04%	41.12%
Newcomers	81.77%	29.47%	37.96%	58.88%

Regulars· Sep 28

AbbVie's JUVMO (tavapadon) has been approved by the FDA for the treatment of Parkinson's disease, making it the first selective D1/D5 agonist for the condition.
In clinical trials, 257 of 273 patients went 85 weeks without ever starting levodopa, a common treatment for Parkinson's, suggesting a promising efficacy for JUVMO.
AbbVie's stock price barely reacted to the news, but the company's Cerevel buyout, which led to the development of JUVMO, is seen as a successful strategy.

Newcomers· Sep 22

Newcomers are excited about AbbVie's REGAL study, which shows promise in treating cancer with a non-myelosuppressive maintenance immunotherapy that is well-tolerated and has durable survivors.
Some newcomers are concerned about the ethics of Rep. Pete Sessions selling AbbVie stock while overseeing healthcare policy, and the lack of transparency around his financial dealings.
AbbVie's stock is trending up due to the company's acquisition of Apogee Therapeutics for $10.9 billion, which aims to deepen its immunology portfolio, and its collaboration with Iambic Therapeutics on AI drug-discovery.

Generated by AI

News

AbbVie's ABBV-295 delivers up to 9.8% weight loss in Phase 1 (ABBV:NYSE)

AbbVie shares: Phase 1 data for weekly ABBV-295 amylin analog shows up to ~10% weight loss, supporting Phase 2 plans—read the key results now.

2h agoSeeking Alpha

AbbVie reports positive phase 2 data for Zumilokibart in atopic dermatitis

5h agoseekingalpha.com

If You Invested $1000 In AbbVie Stock 10 Years Ago, You Would Have This Much Today - AbbVie (NYSE:ABBV)

AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.84% on an annualized basis producing an average annual return of 15.37%. Currently, AbbVie has a market capitalization of $465.70 billion.

13h agoBenzinga

AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know

AbbVie (ABBV) closed the most recent trading day at $263.29, moving 1.12% from the previous trading session.

15h agoYahoo! Finance Canada

AbbVie Inc. stock outperforms competitors despite losses on the day

15h agoMarketWatch

AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo

ABBV wins FDA approval for Juvmo, expanding its Parkinson's portfolio with a once-daily oral treatment and potential $5B-plus PD opportunity.

20h agoYahoo Finance

Also Discussed

Investors talking about ABBV also mention

#	Name	Attention
1	Johnson & JohnsonJNJ	0%-0.06
2	Gilead Sciences, Inc.GILD	0%-0.04
3	Abbott LaboratoriesABT	0%-0.03
4	Bristol-Myers Squibb CompanyBMY	0.01%0
5	Amgen Inc.AMGN	0.01%+0
6	Merck & Co., Inc.MRK	0.01%-0.06
7	Novartis AG Sponsored ADRNVS	0%-0.01
8	Altria Group, Inc.MO	0.06%+0.06
9	Regeneron Pharmaceuticals, Inc.REGN	0%-0.01
10	Biogen IncBIIB	0%-0.01

AbbVie Inc.

Healthcare
Drug Manufacturers - General

AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and commercializes medicines and therapies for complex and serious diseases. AbbVie focuses on major therapeutic areas including immunology, oncology, neuroscience, eye care, aesthetics, and virology, serving patients with chronic autoimmune conditions, blood cancers, inflammatory disorders, and other specialized medical needs. The company’s portfolio includes branded prescription medicines and advanced therapies distributed through physicians, wholesalers, specialty pharmacies, healthcare facilities, and other healthcare channels. AbbVie also supports contract manufacturing services for selected biologics and pharmaceutical processes. Headquartered in North Chicago, Illinois, AbbVie operates as a research-driven healthcare business with a broad international footprint and a strong role in specialty medicine markets.

Website

Location

1 North Waukegan Road

North Chicago, IL, 60064-6400

United States

Social

What share of all stock conversation is about ABBV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.03% -0.03	0.03% +0.02	0.02% +0	0.02% -0.02

Sep 28

AbbVie's JUVMO (tavapadon) has been FDA-approved for Parkinson's disease, making it the first selective D1/D5 agonist for adults with the condition.
257 of 273 patients in a clinical trial went 85 weeks without starting levodopa, a common treatment for Parkinson's disease, indicating the potential effectiveness of JUVMO.
AbbVie's Cerevel buyout has delivered, with the FDA giving the go-ahead to JUVMO as a new treatment and the first selective D1/D5 receptor in adults with Parkinson's disease.

Generated by AI

Sentiment

Of the messages about ABBV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	97.03% -2.97	97.32% +14.23	87.39% -2.68
Bearish	0% 0	2.97% new	2.68% -14.23	12.61% +2.68

Bullish· Aug 27

AbbVie's phase 2 study for spinal cord injuries showed excellent results, with a 100% success rate, and the company is fully funded to Q1 2028.
The market has only 10% penetration for spinal cord injury, with AbbVie's current market cap representing a potential 78% return if the company achieves full market penetration.
AbbVie's stock is expected to experience substantial moves higher, potentially leading to a buyout, with one potential timeframe being October or November.

Bearish· Mar 18

$ABBV's AML treatment failed in several Phase 3 trials, including VIALE-M and VIALE-T, raising concerns about its effectiveness.
AbbVie's stock price declined due to the potential threat of Protagonist Therapeutics' FDA-approved ICOTYDE, a plaque psoriasis treatment that could rival AbbVie's Skyrizi drug.
The stock's sharp breakdown below $220 to $207.93 on higher volume indicates a possible technical breakdown and potential for further downside continuation.

Generated by AI

Topics

Of the messages about ABBV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	6.67%	14.02%	29.32%	37.25%
Announcements	40%	59.03%	33.9%	7.15%
Technical Analysis	53.33%	10.51%	5.74%	1.8%
Earnings	0%	4.85%	3.04%	22.05%
Macro	0%	11.59%	27.83%	31.65%
Controversies	0%	0%	0.17%	0.11%

Earnings· Jul 31

AbbVie (ABBV) reported Q2 2026 earnings with adjusted EPS of $3.65, beating estimates of $3.61, and revenue of $16.99B, also exceeding estimates of $16.77B.
The company's adjusted diluted EPS guidance range was updated from $13.91-$14.11 to $13.87-$14.07, reflecting the anticipated dilutive impact from the proposed acquisition of Apogee Therapeutics.
AbbVie's Q2 2026 earnings were driven by strong performance in its immunology portfolio, with revenue of $8.79B, a 15.1% YoY increase, and adjusted EPS of $3.65, a 22.9% YoY increase.

Analysts· Jun 23

Canaccord Genuity issued a price target of $273.00 for ABBV on June 23, 2026.
The price target was set due to a positive outlook for the company.
The price target of $273.00 is an adjusted amount.

Announcements· Jul 31

AbbVie reported Q2 2026 earnings with revenue of $16.99B, a 10.2% YoY increase, and adjusted EPS of $3.65, a 22.9% YoY increase.
The company raised its full-year revenue guidance by $300M, with Skyrizi and Rinvoq continuing to offset Humira's decline, and all three franchises compounding above 20%.
AbbVie acquired Apogee Therapeutics for $10.9B, adding an IL-13 asset for atopic dermatitis and asthma, and will use this asset in its IL-13/TSLP program.

Controversies· Apr 7

Multiple law firms have announced shareholder class action lawsuits against AbbVie Inc. (NYSE: ABBV) for alleged securities fraud and losses.
The lawsuits aim to recover losses for investors who have suffered damages due to AbbVie's alleged misconduct.
The cases involve several law firms, including Schall Law Firm, Bernstein Liebhard LLP, and Kessler Topaz Meltzer & Check, LLP, which have filed separate lawsuits against AbbVie.

Macro· Mar 18

ABBV is up 3.35% in the last 25 years, according to a comparison with the DGRO ETF.
ABBV's performance is a key consideration for investors weighing the merits of the DGRO ETF.
The comparison highlights the long-term growth potential of ABBV versus the broader market represented by the DGRO ETF.

Technical Analysis· Mar 18

$ABBV has broken below key support areas, triggering stop losses, with a current price of $208.71 and a 5.03% decline.
The daily RSI for $ABBV has hit 30, a level previously reached during major events, such as the Trump tariffs and a failed drug launch.
$ABBV is sitting at critical support, with a sharp breakdown from the mid-$220s to around $211, and some analysts expecting more downside continuation.

Generated by AI

Community

Of the messages about ABBV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	18.23%	70.53%	62.04%	41.12%
Newcomers	81.77%	29.47%	37.96%	58.88%

Regulars· Sep 28

AbbVie's JUVMO (tavapadon) has been approved by the FDA for the treatment of Parkinson's disease, making it the first selective D1/D5 agonist for the condition.
In clinical trials, 257 of 273 patients went 85 weeks without ever starting levodopa, a common treatment for Parkinson's, suggesting a promising efficacy for JUVMO.
AbbVie's stock price barely reacted to the news, but the company's Cerevel buyout, which led to the development of JUVMO, is seen as a successful strategy.

Newcomers· Sep 22

Newcomers are excited about AbbVie's REGAL study, which shows promise in treating cancer with a non-myelosuppressive maintenance immunotherapy that is well-tolerated and has durable survivors.
Some newcomers are concerned about the ethics of Rep. Pete Sessions selling AbbVie stock while overseeing healthcare policy, and the lack of transparency around his financial dealings.
AbbVie's stock is trending up due to the company's acquisition of Apogee Therapeutics for $10.9 billion, which aims to deepen its immunology portfolio, and its collaboration with Iambic Therapeutics on AI drug-discovery.

Generated by AI

AbbVie

Social

Sep 28

Bullish· Aug 27

Bearish· Mar 18

Earnings· Jul 31

Analysts· Jun 23

Announcements· Jul 31

Controversies· Apr 7

Macro· Mar 18

Technical Analysis· Mar 18

Regulars· Sep 28

Newcomers· Sep 22

AbbVie's ABBV-295 delivers up to 9.8% weight loss in Phase 1 (ABBV:NYSE)

AbbVie reports positive phase 2 data for Zumilokibart in atopic dermatitis

If You Invested $1000 In AbbVie Stock 10 Years Ago, You Would Have This Much Today - AbbVie (NYSE:ABBV)

AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know

AbbVie Inc. stock outperforms competitors despite losses on the day

AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo

Also Discussed

AbbVie Inc.

Company Information

Location

AbbVie's ABBV-295 delivers up to 9.8% weight loss in Phase 1 (ABBV:NYSE)

AbbVie reports positive phase 2 data for Zumilokibart in atopic dermatitis

If You Invested $1000 In AbbVie Stock 10 Years Ago, You Would Have This Much Today - AbbVie (NYSE:ABBV)

AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know

AbbVie Inc. stock outperforms competitors despite losses on the day

AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo

Also Discussed

Social

Sep 28

Bullish· Aug 27

Bearish· Mar 18

Earnings· Jul 31

Analysts· Jun 23

Announcements· Jul 31

Controversies· Apr 7

Macro· Mar 18

Technical Analysis· Mar 18

Regulars· Sep 28

Newcomers· Sep 22